What Does Pro Medicus' (ASX:PME) A$24 Million Billings Clinic Deal Mean for Its Cloud Imaging Push?

Sonal Goyal

05 November 2026 06:16 PM AEDT

What Does Pro Medicus' (ASX:PME) A$24 Million Billings Clinic Deal Mean for Its Cloud Imaging Push?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Pro Medicus signed a 7-year, A$24 million contract with Billings Clinic - Logan Health for its Visage 7 cloud platform

• The deal includes the full stack — Visage 7 Viewer, Workflow, and Open Archive — plus legacy PACS migration

• Go-live is targeted for Q1 of the 2027 calendar year, with the transaction-based model offering potential upside

Pro Medicus Ltd (ASX:PME) closed at A$208.23 on 05 November 2026, rising 10.39% on the session. The S&P/ASX 200 (XJO) gained 2.61%, or 230.60 points, to 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) advanced 3.64%, or 1,240.30 points, to 35,329.10. Overnight gains on Wall Street, following the Democrats' decisive victory in the U.S. midterm elections, supported global Equity sentiment. Pro Medicus is a leading health imaging informatics company that provides medical imaging software and services to hospitals and imaging centres worldwide through its Visage 7 platform.

Billings Clinic - Logan Health Contract Details

On 19 October 2026, Pro Medicus announced that its wholly-owned U.S. subsidiary, Visage Imaging, Inc., had signed a 7-year, A$24 million contract with Billings Clinic - Logan Health, a unified, not-for-profit independent health system based in Montana. Billings Clinic - Logan Health operates 25 hospitals with more than 1,000 beds, including 16 regional partnerships with critical access hospitals and clinics, serving communities across Montana, Northern Wyoming, and the western Dakotas.

The contract covers the Visage 7 full stack, comprising Visage 7 Viewer, Visage 7 Workflow, and Visage 7 Open Archive, providing a single, unified enterprise imaging platform. The deal also includes the migration of legacy PACS archives to Visage 7 Open Archive and the distribution of images integrated into Billings Clinic - Logan Health's electronic health record (EHR). The agreement operates on a transaction-based model with potential upside.

Cloud-Based Implementation and Strategy

The Visage 7 platform will be implemented in the cloud, consistent with Pro Medicus' CloudPACS strategy. Go-live is targeted for Q1 of the 2027 calendar year. CEO Dr Sam Hupert stated that Billings Clinic - Logan Health joins a growing list of clients opting for the fully cloud-based platform, which is becoming the standard in the North American healthcare IT market. Dr Hupert also noted the company continues to grow its North American footprint across a broad range of market opportunities.

About Pro Medicus

Pro Medicus was founded in 1983 and acquired Visage Imaging in January 2009, transforming it into a global provider of medical imaging solutions. The Visage 7 suite is designed as an ultra-fast, clinically rich, and highly scalable platform deployable in both public and private cloud environments. The company offers RIS, PACS, Artificial Intelligence, and e-health solutions across its offices in Melbourne, Berlin, and San Diego.

Sector Context

The healthcare sector on the ASX experienced a broad rally on 05 November 2026, with the Health Care sub-index rising 3.64%. Within the health imaging technology space, there has been an ongoing shift toward cloud-based enterprise imaging platforms, driven by healthcare systems seeking to consolidate disparate legacy PACS systems and improve workflow efficiency. Pro Medicus has been a beneficiary of this trend, with its transaction-based licensing model providing Recurring Revenue visibility.

Risks

Pro Medicus' revenue is concentrated in the North American healthcare IT market, exposing it to regulatory changes in U.S. healthcare policy and reimbursement structures. The company's premium valuation means any slowdown in contract wins could lead to share price volatility. Foreign exchange movements between the Australian and U.S. dollars also present translation risk. Additionally, competition from established PACS vendors and emerging cloud imaging providers remains a consideration.

Catalysts on Watch

The pipeline of new contract wins across all market segments is a key indicator for investors. The adoption of the full-stack solution, encompassing viewer, workflow, archive, and cardiology modules, could drive higher average contract values. The expansion of cloud-based deployments and the migration of legacy archives represent further growth opportunities. Any additional large health system wins in North America or expansion into new geographies could provide catalysts.

Looking Ahead

Pro Medicus' A$24 million contract with Billings Clinic - Logan Health adds another multi-state health system to its growing cloud client base. The deal aligns with the broader industry trend toward consolidated enterprise imaging platforms and reinforces the company's CloudPACS strategy in North America.

FAQs

Q: What is the value and duration of Pro Medicus' Billings Clinic deal?

A: The contract is valued at A$24 million over a 7-year term.

Q: What products are included in the Billings Clinic contract?

A: The deal includes the Visage 7 full stack — Viewer, Workflow, and Open Archive — plus legacy PACS migration and EHR integration.

Q: When is the Billings Clinic implementation expected to go live?

A: Go-live is targeted for Q1 of the 2027 calendar year.

Q: What is Pro Medicus' business model?

A: Pro Medicus provides medical imaging software through its Visage 7 platform, typically under transaction-based licensing models that offer recurring revenue with potential upside.

Q: Where does Pro Medicus operate?

A: Pro Medicus has offices in Melbourne, Berlin, and San Diego, and serves hospitals, imaging centres, and health care groups globally.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.